| Ytd | 15.63% | |
| 1y | -3.29% |
| Open | 0.82 | Prev Close | 0.82 | Low | 0.82 | High | 0.83 | Mkt Cap | 137.38M |
| Vol | 61.46K | Avg Vol | 3.61M | EPS | -0.47 | P/E | -1.75 | Forward P/E | -1.28 |
| Beta | 2.83 | Short Ratio | 2.31 | Inst. Own | 73.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 0.80 | 200-d Avg | 0.95 | 1yr Est | 18.50 |
TNYA News
SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TN
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Exper
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Re
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy f
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefit
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction C
Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.09 per share in line with the
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-A
SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T
Belite Bio (NASDAQ: BLTE - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report)
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional D
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are up on Thursday, reflecting a positive market res
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals wor
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targ
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T
On Tuesday, 838 companies hit new 52-week lows.
During Monday's session, 402 companies made new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.